Ultrasound guided corticosteroids sacroiliac joint injections (SIJIs) in the management of active sacroiliitis: a real-life prospective experience

Autor: Suhel G. Al Khayyat, Giuseppe Fogliame, Stefano Barbagli, Edoardo Conticini, Marta Fabbroni, Roberto D’Alessandro, Antonio Vitale, Stefano Gentileschi, Marco Bardelli, Caterina Baldi, Salvatore Massimo Stella, Annarita Saponara, Andrea Del Chiaro, Paolo Falsetti, Luca Cantarini, Bruno Frediani
Rok vydání: 2022
Předmět:
Zdroj: Journal of ultrasound.
ISSN: 1876-7931
Popis: Active sacroiliitis represents the hallmark of axial spondyloarthritis (axSpA) and manifests as inflammatory low back pain associated with morning stiffness (MS). Sometimes, the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and biological disease modifying drugs (bDMARDs) proves unsatisfactory in achieving a remission.We enrolled patients affected with active sacroiliitis confirmed via magnetic resonance imaging (MRI) and treated with a corticosteroid sacroiliac joint injection (SIJI) via ultrasound guidance. After SIJI, we evaluated visual-analogue scale (VAS) and MS pain changes. As controls, we selected axSpA patients starting bDMARDs.We enrolled 26 patients (mean age 55 ± 14 years; 25 females and 1 male; 95% treated with NSAIDs; 46% on bDMARDs; 75.82 ± 123 months) and examined a total of 47 treated joints. We detected a 48% reduction in VAS pain after 24 h. Moreover, we observed a significant reduction (p 0.0001) of VAS pain between the baseline and every subsequent follow-up visit. Further, a significant difference in VAS pain compared to the baseline in the controls was observed starting from week 12. There was a significant reduction in MS after 1 week due to SIJIs, while in the controls the first significant change from the baseline in MS was detected after 12 weeks. The efficacy of infiltrative therapy lasted up to 6 months: persistent VAS as well as MS pain reduction was observed.US-guided SIJI represents an effective and safe technique for patients who have active sacroiliitis yet are ineligible for biologic treatment or who experience unsatisfactory disease control despite receiving therapy.
Databáze: OpenAIRE